StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson infectious Diseases (ID) Therapeutic Area Total — U.S. sales ($M) ($M)

Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule

Latest, FY2025
1,264
Period ended Dec 28, 2025
Change on a year earlier
-6.6%
1,354 in FY2024
History
10 years
Since FY2016
Sources
7
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedInfectious Diseases (ID) Therapeutic Area Total — U.S. sales ($M) ($M)Year on yearSource
FY2025Dec 28, 20251,264-6.6%Form 10-K (filed 2026-02-11) ↗
FY2024Dec 29, 20241,354-9.7%Form 10-K (filed 2026-02-11) ↗
FY2023Dec 31, 20231,500-10.7%Form 10-K (filed 2026-02-11) ↗
FY2022Jan 1, 20231,680-25.3%Form 10-K (filed 2025-02-13) ↗
FY2021Jan 2, 20222,249+29.6%Form 10-K (filed 2024-02-16) ↗
FY2020Jan 3, 20211,735+8.6%Form 10-K (filed 2023-02-16) ↗
FY2019Dec 29, 20191,597+15.9%Form 10-K (filed 2022-02-17) ↗
FY2018Dec 30, 20181,378+1.5%Form 10-K (filed 2021-02-22) ↗
FY2017Dec 31, 20171,358-7.0%Form 10-K (filed 2019-02-20) ↗
FY2016Jan 1, 20171,461–Form 10-K (filed 2019-02-20) ↗

Breakdown

What makes up infectious diseases (id) therapeutic area total — u.s. sales ($m)

Cite this data

StockData. (2026). Johnson & Johnson Infectious Diseases (ID) Therapeutic Area Total — U.S. sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta_infectious_diseases_us

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.